Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for ...

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed ...

Teams from various departments have sprung into action to prevent and control vector-borne diseases like dengue, malaria, and ...

The phase III clinical trial enrolment for India's first one-shot dengue vaccine, DengiAll, developed by Panacea Biotec, is set to complete with 10,500 participants across 20 centers. This trial aims ...

The enrolment for phase III clinical trials of India's first dengue vaccine, DengiAll, is expected to be completed by October ...

An ongoing Phase III clinical trial of DengiAll, a one-shot dengue vaccine developed by Panacea Biotec, is progressing in ...

The one-shot vaccine, developed by Panacea Biotec and branded as DengiAll, is being tested through a multi-centre, double-blind, randomised, placebo-controlled trial.

Health officials are warning travellers of a mosquito-borne virus that can cause debilitating joint pain, after cases emerged ...

Dumarami na naman ang kaso ng dengue lalo na ngayong tag-ulan. Kaya parents, mahalagang alam natin ang sintomas ng dengue sa ...

Since the start of the SARS-CoV-2 pandemic, several variants of the virus have developed into Variants of Concern (VOCs), as ...